Login to Your Account

MAP Phase III Asthma Study Fails to Hit Mark in Pediatric Patients

By Catherine Hollingsworth

Wednesday, February 25, 2009
MAP Pharmaceuticals Inc. said that its potential treatment for asthma in children did not improve symptoms any better than placebo in a Phase III study of unit dose budesonide (UDB), leaving the program in limbo for now and causing its shares to fall more than 75 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription